Aggravation of the Existing Respiratory Diseases by the Loss or Difficulty in Supplying of Medicines and Medical Application: What Happened and What Measurements Should the Community and the Patient and His Family Do When the Medicines for the Existing Respiratory Disease Are Lost or Not Supplied?
Japan is subject to frequent natural disasters. In patients with respiratory diseases, continuous treatment is needed from the acute phase through the chronic phase of a disaster. When a disaster is divided into the acute, subacute, and chronic phases, medication shortages are expected during the acute phase, which delays the distribution of medications and prevents patients from obtaining enough medications. Given this premise, measures are needed to allow many patients to receive treatment equally during the acute phase. During patient education, medical professionals should encourage patients to stockpile necessary medications to be prepared for the acute phase of a disaster and should provide action plans for patients. During the subacute phase, medication stockpiles start to increase, thereby gradually allowing for the provision of regular treatment to patients. During the chronic phase, many residents tend to live in isolation, and patients need continued support.
KeywordsMedication shortages Acute phase of a disaster Chronic phase of a disaster The distribution of medications Action plans for patients
- 1.Kirch L, Luther S, Mucke P et al. WorldRiskReport- Analysis and prospects 2017. Bündnis Entwicklung Hilft. 2017. https://reliefweb.int/report/world/world-risk-report-2017. Accessed 6 Feb 2018
- 2.Japan Institute of Country-ology and Engineering. http://www.jice.or.jp/knowledge/japan/commentary12#jump_01. Accessed 6 Feb 2018 (in Japanese)
- 3.Early Warning Sub-Committee of the Inter-Ministerial Committee on International Cooperation for Disaster Reduction Government of Japan. Japan’s Natural Disaster Early Warning Systems and International Cooperative Efforts. Cabinet Office, Government of Japan. 2006. http://bousaigojp/kokusai/kyoryoku Accessed 6 Feb 2018 (in Japanese)
- 6.Japan Pharmaceutical Association. 2015. http://www.nichiyaku.or.jp/saigai2016/files/sr20160415.pdf#search=%27%E7%81%BD%E5%AE%B3%E3%80%81%E8%96%AC%E5%89%A4%E5%82%99%E8%93%84%27. Accessed 6 Feb 2018 (in Japanese)
- 8.Kobayashi S, Hanagama M, Yamanda S, Satoh H, Tokuda S, Kobayashi M, Ueda S, Suzuki S, Yanai M. The impact of a large-scale natural disaster on patients with chronic obstructive pulmonary disease: the aftermath of the 2011 Great East Japan Earthquake. Respir Investig. 2013;51:17–23.CrossRefGoogle Scholar
- 12.Japan Pharmaceutical Wholesalers Association. 2015. www.jpwa.or.jp/jpwa/pdf/topics_201601_01.pdf. Accessed 6 Feb 2018 (in Japanese)
- 17.Mikasa K, Aoki N, Aoki Y, et al. Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy—The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee Respiratory Infectious Disease WG. J Infect Chemotherapy. 2016;22:S1–S65.CrossRefGoogle Scholar
- 18.Yokohama Pharmaceutical Association. http://www.hamayaku.or.jp/saigai-2016-5.html. Accessed 6 Feb 2018 (in Japanese)
- 19.Oita Pharmaceutical Association. http://www.oitakenyaku.or.jp/manage/wp-content/uploads/2014/09/Mobile-Pharmacy.pdf. Accessed 6 Feb 2018 (in Japanese)